Presentation is loading. Please wait.

Presentation is loading. Please wait.

Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with.

Published byAudra Hicks Modified over 6 years ago

Similar presentations

Presentation on theme: "Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with."— Presentation transcript:

1 Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality  Waleed Sabry, Richard Le Blanc, Annie-Claude Labbé, Guy Sauvageau, Stephen Couban, Thomas Kiss, Lambert Busque, Sandra Cohen, Silvy Lachance, Denis-Claude Roy, Jean Roy  Biology of Blood and Marrow Transplantation  Volume 15, Issue 8, Pages (August 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Shown are patients who achieved ≥95% donor cells in granulocytes and lymphocytes following NMA transplant. Patients with either relapse (R), missing specimens (ND), or who died (D) were excluded from denominators. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Compares incidences of classic grade II-IV aGVHD (7.7 %) and overlap syndrome (12 %). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Shows an incidence of non relapse mortality of 15.5% (95% CI: ) at 7 years in a cohort of 131 patients who received NMA transplant. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Shows an OS of 62.7% (95% CI : ) at 7 years for the whole cohort of 131 patients. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 Shown is the estimated OS in our 131 patients according to initial diagnosis. NHL, non Hodgkin lymphoma; MM, multiple myeloma; DLCL, diffuse large-cell lymphoma. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 Shown is the estimated DFS in 131 patients according to initial diagnosis. NHL, non Hodgkin lymphoma; MM, multiple myeloma; DLCL, diffuse large-cell lymphoma. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with."

Similar presentations

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.
Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.
Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach  Jean Roy, MD, FRCPC, Imran Ahmad,

Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach  Jean Roy, MD, FRCPC, Imran Ahmad,
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
The Role of Missing Killer Cell Immunoglobulin-Like Receptor Ligands in T Cell Replete Peripheral Blood Stem Cell Transplantation from HLA-Identical Siblings 

The Role of Missing Killer Cell Immunoglobulin-Like Receptor Ligands in T Cell Replete Peripheral Blood Stem Cell Transplantation from HLA-Identical Siblings 
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.
Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies  Katarina Le.

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies  Katarina Le.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation 

Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation 
Plasma Biomarkers in Graft-versus-Host Disease: A New Era?

Plasma Biomarkers in Graft-versus-Host Disease: A New Era?
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,

Similar presentations

Ads by Google